Core Viewpoint - The strategic cooperation agreement between Chengda Biological and the Institute of Microbiology focuses on addressing emerging infectious diseases, particularly vector-borne diseases, through joint research and project applications for national and provincial funding [1][2][4]. Company Overview - Chengda Biological is a biopharmaceutical company specializing in the research, production, and sales of human vaccines, with a leading market position in rabies and Japanese encephalitis vaccines in China [1]. - The company has established production bases in Shenyang and Benxi, and has a dedicated R&D team of over 200 personnel, with independent research capabilities and a comprehensive management system [1]. Research Collaboration - The collaboration aims to leverage the strengths of both parties, combining the Institute's research capabilities with Chengda's development and production resources to enhance vaccine and biopharmaceutical research [2][4]. - The focus will be on joint applications for national and provincial research projects to secure government support and resources, fostering innovation and high-quality industrial development [2][3]. Strategic Goals - The partnership is expected to accelerate the development of vaccines and biopharmaceuticals for emerging infectious diseases, enriching Chengda's innovation pipeline and strengthening its core competitiveness in the field of infectious disease prevention [4]. - The agreement is characterized as an intention-based collaboration, with no immediate impact on the company's financial performance for 2025, as the effects will depend on the progress of specific projects [4].

Group 1 - Pinggao Electric reported a 6.98% increase in revenue to 8.436 billion yuan and a 14.62% increase in net profit to 982 million yuan for the first three quarters of 2025 [1] - Wanchen Group achieved a 77.37% increase in revenue to 36.562 billion yuan and a staggering 917.04% increase in net profit to 855 million yuan for the first three quarters of 2025 [2] - Xintian's revenue decreased by 10.42% to 481 million yuan, with a net profit decline of 35.19% to 91.9 million yuan for the first three quarters of 2025 [3] Group 2 - Chuangye Heima reported a revenue drop of 35.68% to 102 million yuan and a net loss of 24.93 million yuan for the first three quarters of 2025 [4] - Huaxin New Materials saw a 16.11% increase in revenue to 265 million yuan and an 18.56% increase in net profit to 40.81 million yuan for the first three quarters of 2025 [5] - Meihua Medical's revenue increased by 3.28% to 1.194 billion yuan, but net profit fell by 19.25% to 208 million yuan for the first three quarters of 2025 [6] Group 3 - Silica Technology reported a 24.30% increase in revenue to 2.651 billion yuan and a 44.63% increase in net profit to 229 million yuan for the first three quarters of 2025 [7] - Anada experienced a revenue decline of 6.03% to 1.31 billion yuan and a net loss of 46.37 million yuan for the first three quarters of 2025 [8] - StarNet Ruijie achieved a 19.20% increase in revenue to 14.168 billion yuan and a 31.06% increase in net profit to 344 million yuan for the first three quarters of 2025 [9] Group 4 - New Link Electronics reported a revenue decrease of 0.37% to 550 million yuan but a significant net profit increase of 421.43% to 535 million yuan for the first three quarters of 2025 [10] - Tianyin Electromechanical's revenue fell by 22.75% to 581 million yuan, with a net profit decline of 56.10% to 24.27 million yuan for the first three quarters of 2025 [11] - Hengtong Co. reported a revenue decrease of 39.29% to 1.05 billion yuan, but a net profit increase of 78.33% to 176 million yuan for the first three quarters of 2025 [12] Group 5 - Xigao Institute achieved a 15.05% revenue increase to 651 million yuan and a 21.28% net profit increase to 198 million yuan for the first three quarters of 2025 [13] - Good Housewife reported a revenue decrease of 0.91% to 1.059 billion yuan and a net profit decline of 24.79% to 143 million yuan for the first three quarters of 2025 [14] - China Pharmaceutical's subsidiary received approval for Vitamin B6 injection, indicating a positive development in its product pipeline [20] Group 6 - Xi Zhong Technology received approval for the issuance of convertible bonds, indicating potential for future capital raising [22] - Chengda Bio signed a strategic cooperation agreement with the Chinese Academy of Microbiology, focusing on infectious disease prevention [25] - Fuyuan Pharmaceutical received a drug registration certificate for Dydrogesterone tablets, enhancing its product offerings [26] Group 7 - Zhehai Deman received 8.1202 million yuan in land acquisition compensation, indicating a successful resolution of land-related issues [27] - Zhongjin Irradiation announced the resignation of its deputy general manager, indicating potential changes in management [29] - Hendi Pharmaceutical received a drug registration certificate for Febuxostat tablets, expanding its product portfolio [30] Group 8 - David Medical's subsidiary received a medical device registration certificate for a surgical stapler, enhancing its product offerings [32] - Liaoning Energy announced plans for a share reduction by a major shareholder, indicating potential changes in ownership structure [34] - Fengyuan Co. signed a framework agreement for the supply of lithium iron phosphate, indicating growth in its supply chain [35] Group 9 - Shengda Resources announced the resumption of construction at a mining site, indicating recovery from previous operational disruptions [37] - Shiyuan Co. reported a revenue increase of 5.45% to 18.087 billion yuan, but a net profit decline of 6.81% to 867 million yuan for the first three quarters of 2025 [39] - Feilida reported a revenue decrease of 6.81% to 4.659 billion yuan, but a net profit increase of 49.1% to 33.19 million yuan for the first three quarters of 2025 [40] Group 10 - Changyuan Donggu reported a revenue increase of 29.75% to 1.648 billion yuan and a net profit increase of 76.71% to 274 million yuan for the first three quarters of 2025 [41] - Liyuanheng reported a net profit of 47.49 million yuan for the first three quarters of 2025, indicating stable performance [42] - Fangyuan Co. reported a net loss of 121 million yuan for the first three quarters of 2025, indicating challenges in its operations [43] Group 11 - China Mobile reported a revenue increase of 0.4% to 794.7 billion yuan and a net profit increase of 4% to 115.4 billion yuan for the first three quarters of 2025 [44] - Huangshanghuang reported a revenue decrease of 5.08% to 1.379 billion yuan but a net profit increase of 28.59% to 101 million yuan for the first three quarters of 2025 [46] - Youcai Resources announced plans to invest approximately 150 million yuan in a new materials production base project [47] Group 12 - Huawei Technology announced plans to invest up to 20 million euros in two German subsidiaries [49] - China Shipbuilding projected a net profit increase of 144.42% to 170.85% for the first three quarters of 2025, indicating strong performance [51] - Aeston's subsidiary plans to transfer a 48% stake in a company for 245 million yuan, indicating strategic divestment [52] Group 13 - Jinxinno plans to raise up to 292 million yuan through a private placement, indicating potential for expansion [53] - China Power Construction reported a 5.04% increase in new contract amounts to 904.527 billion yuan for the first three quarters of 2025 [54] - Helitai reported a net profit increase of 101.45% to 17.81 million yuan for the first three quarters of 2025 [55] Group 14 - Xuefeng Technology reported a revenue decrease of 8.28% to 4.183 billion yuan and a net profit decline of 34.6% to 394 million yuan for the first three quarters of 2025 [57] - Juzhi Technology reported a revenue increase of 21.40% to 615 million yuan and a net profit increase of 33.78% to 82.47 million yuan for the first three quarters of 2025 [59] - Jinxi Axle reported a revenue decrease of 0.11% to 872 million yuan but a net profit increase of 268.03% to 22.11 million yuan for the first three quarters of 2025 [60] Group 15 - Longsheng Technology reported a revenue increase of 10.13% to 1.810 billion yuan and a net profit increase of 36.89% to 210 million yuan for the first three quarters of 2025 [62] - Shannon Chip Creation announced plans for a share reduction by a major shareholder, indicating potential changes in ownership structure [63]

证券代码：688739 证券简称：成大生物 公告编号：2025-052 辽宁成大生物股份有限公司 关于自愿披露签订战略合作协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 合同类型：辽宁成大生物股份有限公司（简称"公司"或"成大生物"） 与中国科学院微生物研究所（简称"微生物所"）于近日签署《战略合作协议》 （简称"本协议"），双方聚焦新发突发传染病领域，重点围绕虫媒传染病预防， 联合申报国家级、省部级科研项目，协同发力应对传染病防控。 对公司当年业绩的影响：本协议属于意向性合作范畴，对公司 2025 年度 及未来业绩不构成直接影响，对公司业绩的具体影响需视下一步具体项目推进 和实施情况来确定。 履约的重大风险及不确定性： 本协议的签订对双方长期合作具有指导性意义，确立了战略合作伙伴关系， 为后续推进具体项目合作奠定重要基础，本次签订的战略合作协议属于意向性 合作协议，具体合作内容以双方签订的项目合作合同为准。协议履行过程中， 若受行业政策调整、市场环境变化等不可预见因素或不可抗力影响，可能导致 协 ...

Core Insights - Chengda Biologics (688739.SH) has signed a strategic cooperation agreement with the Institute of Microbiology, Chinese Academy of Sciences, focusing on emerging infectious diseases [1] - The collaboration aims to jointly apply for national and provincial-level research projects, enhancing efforts in infectious disease prevention and control [1] - This strategic partnership integrates top resources in pathogen research from the Institute of Microbiology with the existing vaccine development platform of the company, accelerating the development of vaccines and biopharmaceuticals for emerging infectious diseases [1]

Core Viewpoint - Chengda Bio (688739) has signed a strategic cooperation agreement with the Institute of Microbiology, Chinese Academy of Sciences, focusing on emerging infectious diseases and vector-borne disease prevention [1] Group 1 - The cooperation aims to jointly apply for national and provincial-level research projects to enhance efforts in infectious disease prevention and control [1] - The agreement is categorized as an intention-based collaboration and does not have a direct impact on the company's performance for 2025 and beyond [1]

Core Insights - Chengda Biological (688739.SH) has signed a strategic cooperation agreement with the Institute of Microbiology, Chinese Academy of Sciences, focusing on emerging infectious diseases [2] Group 1 - The collaboration will concentrate on the prevention of vector-borne infectious diseases [2] - Both parties will jointly apply for national and provincial-level research projects [2] - The partnership aims to enhance efforts in infectious disease prevention and control [2]

格隆汇10月21日丨成大生物(688739.SH)公布，公司与中国科学院微生物研究所(简称"微生物所")于近日 签署《战略合作协议》(简称"本协议")，双方聚焦新发突发传染病领域，重点围绕虫媒传染病预防，联 合申报国家级、省部级科研项目，协同发力应对传染病防控。 本次战略合作整合了微生物所病原学研究顶尖资源，与公司现有疫苗研发平台形成协同效应，将加速新 发突发传染病疫苗及生物药研发进程，进一步丰富公司创新管线布局。 ...

Core Viewpoint - The company has signed a strategic cooperation agreement with the Institute of Microbiology, Chinese Academy of Sciences, focusing on emerging infectious diseases, particularly vector-borne disease prevention [1] Group 1 - The agreement aims to jointly apply for national and provincial-level research projects to enhance efforts in infectious disease prevention and control [1] - This cooperation is categorized as an intention-based collaboration and does not have a direct impact on the company's performance for the year 2025 and beyond [1] - The specific impact on the company's performance will depend on the progress and implementation of subsequent projects [1]

Core Viewpoint - Chengda Biotech is focusing on the development, production, and sales of human vaccines, with a strong market presence in rabies and encephalitis vaccines, while also expanding its international business and exploring innovative technologies [1][2][3] Group 1: Company Overview - Chengda Biotech specializes in human vaccine research and production, with significant products including rabies and inactivated encephalitis vaccines [1] - The company has established production bases in Shenyang and Benxi, and has a dedicated R&D team of over 200 personnel [1] - Chengda Biotech's rabies vaccine has maintained a leading position in the domestic market since 2008, and it is the only provider of inactivated encephalitis vaccine in China [1] Group 2: Financial Performance - In the first half of 2025, the company reported revenue of 707 million yuan, a year-on-year decrease of 19.75% [1] - Total profit for the same period was 146 million yuan, down 46.37%, while net profit attributable to shareholders was 122 million yuan, a decline of 44.47% [1] Group 3: Governance and Strategic Initiatives - In February 2025, the company underwent a significant governance restructuring, changing its controlling shareholder to Shaoguan Gaoteng, which has no actual controller [2] - This governance change aims to enhance decision-making efficiency and market operations, while also exploring mergers and acquisitions for growth [2] Group 4: International Expansion - Chengda Biotech's international business has shown strong performance, with rabies vaccine sales increasing and market access expanded to over 30 countries, including new entry into Indonesia [2] - The company is actively pursuing market opportunities in countries along the Belt and Road Initiative, such as Brazil [2] Group 5: R&D and Innovation - The company has made significant progress in R&D, with several products at critical stages, including the human diploid rabies vaccine and various flu vaccines [3] - Chengda Biotech has established an "AI + Vaccine R&D Joint Laboratory" in collaboration with Zhongke Zhidong Taichu to explore deep applications of AI technology [3] - The marketing strategy for the inactivated encephalitis vaccine has shown effectiveness, with increased coverage and penetration in vaccination endpoints [3]

证券日报网讯 10月9日晚间，成大生物发布公告称，2025年9月份，公司通过上海证券交易所交易系统 以集中竞价交易方式回购公司股份208，478股，占公司总股本的比例约为0.05%。 ...